Advances in Detecting Latent Tuberculosis Infection in High-Risk Groups: from Immunodiagnostics to Machine Learning (Systematic Review)

The detection of latent tuberculosis infection (LTBI) is essential for improving the epidemiological situation in the region. As tuberculosis prevalence declines, identifying LTBI in risk groups becomes increasingly significant. At present, no method exists that can reliably confirm or exclude the presence of latent tuberculosis infection. In this study, we analyzed 71 publications on methods for LTBI detection, including modern immunological tests based on Mycobacterium tuberculosis antigens ESAT-6 and CFP-10, as well as interferon-γ release assays (IGRAs). Developing diagnostic strategies for LTBI is particularly relevant for individuals with diabetes mellitus, congenital or acquired immunodeficiency, those receiving immunosuppressive therapy, patients undergoing hemodialysis, as well as for children and the elderly. The search for novel LTBI biomarkers using artificial intelligence, aimed at improving detection and predicting the progression to active tuberculosis seems to be promising advancement in phthisiology.

1. Aksenova V.A., Baronova O.D., Baryshnikova L.A., Kazakov A.V., Klevno N.I. et al. Latentnaya tuberkuleznaya infektsiya u detey. Klinicheskie rekomendatsii. [Latent tuberculous infection in children. Guidelines]. Moscow, ROOI Zdorovye Cheloveka Publ., 2024.

2. Aksenova V.A., Levi D.T., Aleksandrova N.V. et al. Tuberculosis in children: contemporary methods of prevention and early detection. Doktor.Ru, 2017, vol. 144, no. 15, pp. 9-15. (In Russ.)

3. Aksenova V.A., Nakonechnaya S.L., Mizernitskiy Yu.L., Klevno N.I., Kazakov A.V., Kudlai D.A. Diagnosis of tuberculosis in children with chronic non-specific lung diseases. Tuberculosis and Lung Diseases, 2025, vol. 103, no. 1, pp. 8-13. (In Russ.) http://doi.org/10.58838/2075-1230-2025-103-1-8-13

4. Bogorodskaya E.M., Slogotskaya L.V., Shamuratova L.F., Sevostyanova T.A. Screening for tuberculosis infection in children and adolescents by two intracutaneous tests: with tuberculin and tuberculosis recombinant allergen (ESAT-6/CFP-10) in Moscow in 2021. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 11, pp. 29-38. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-11-29-38

5. Borodulina E.A., Kudlay D.A., Kuznetsova A.N., Gladunova E.P., Kalashnikova E.V. The use of the ELISPOT technological platform in the diagnosis of tuberculosis infection in patients with HIV infection. Immunologiya, 2021, vol. 42, no. 4, pp. 395-402. (In Russ.) https://doi.org/10.33029/0206-4952-2021-42-4-395

6. Vasilyeva I.A., Sterlikov S.A., Testov V.V., Mikhaylov A.Yu., Golubev N.A., Kucheryavaya D.A., Ponomarev S.B. Resursy i deyatelnost protivotuberkuleznykh organizatsiy Rossiyskoy Federatsii v 2023-2024 gg. [Resources and activities of TB units in the Russian Federation in 2023-2024]. Moscow, FGBU NMITS FPI Minzdrava Rossii Publ., 2025.

7. Vishnevskiy B.I., Yablonskiy P.K. The persistence of Mycobacterium tuberculosis аs the basis of latent tuberculosis (review). Meditsinsky Alyans, 2020, vol. 8, no. 2, pp. 14-20. (In Russ.)

8. Gordeev A.A., Plekhanova M.A., Smerdin S.V., Tkachuk A.P., Manuylov V.A., Kudryashova A.M., Cherepovich B.S., Borisova O.V. A comparative study of six immunological tests for the diagnosis of tuberculosis in different patient groups. Tuberculosis and Lung Diseases, 2025, vol. 103, no. 3, pp. 94-102. (In Russ.) http://doi.org/10.58838/2075-1230-2025-103-3- 94-102

9. Kazakov A.V., Klevno N.I., Sokolskaya E.A., Prikhodko A.A., Pakhlavonova A.D., Kudlay D.A. The role of modern immunological tests in the differential diagnosis of paediatric tuberculosis. Meditsinsky Soviet, 2025, vol. 19, no. 1, pp. 126-132. (In Russ.) https://doi.org/10.21518/ms2025-062

10. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2024 year. Gosudarstvenny doklad. [State report on the state on sanitary and epidemiological welfare of population in the Russian Federation in 2024]. Moscow, Federal Surveillance Service for Protection of Consumers' Rights and Well-being Publ., 2025.

11. Sinitsyn M.V., Bogorodskaya E.M., Ayusheeva L.B., Belilovsky E.M. Latent tuberculosis infection among HIV-infected people in Moscow. Tuberculosis and Socially Significant Diseases, 2017, no. 2, pp. 42-44. (In Russ.)

12. Slogotskaya L.V., Lovacheva O.V., Klevno N.I. Stages of tuberculosis infection, What's new? (literature review). Tuberculosis and Lung Diseases, 2025, vol. 103, no. 2, pp. 93-101. (In Russ.) – https://doi.org/10.58838/2075-1230-2025-103-2-93-101

13. Abedi S., Moosazadeh M., Afshari M., Charati J.Y., Nezammahalleh A. Determinant factors for mortality during treatment among tuberculosis patients: Cox proportional hazards model. Indian J. Tuberc., 2019, vol. 66, no. 1, pp. 39-43. https://doi.org/10.1016/j.ijtb.2017.05.001

14. Boom W.H., Schaible U.E., Achkar J.M. The knowns and unknowns of latent Mycobacterium tuberculosis infection. J. Clin. Invest., 2021, vol. 131, no. 3, pp. e136222. https://doi.org/10.1172/JCI136222

15. Boqaeid A., Layqah L., Alonazy A., Althobaiti M., Almahlawi A.Z., Al-Roqy A., Baharoon O., Alsaeedi A., Shamou J., Baharoon S. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy. J. Infect. Public Health, 2024, vol. 17, no. 6, pp. 1134-1141. https://doi.org/10.1016/j.jiph.2024.04.016

16. Boumait Y., Ettetuani B., Chrairi M., Lamzouri A., Chahboune R. Identification of gene expression biomarkers predictive of latent tuberculosis infection using machine learning approaches. Genes (Basel), 2025, vol. 16, no. 6, pp. 715. https://doi.org/10.3390/genes16060715

17. Buron V., Banaei N. Inflated gamma interferon response with QuantiFERON-TB Gold Plus using the automated Liaison XL Analyzer: a testing algorithm to mitigate false-positive results in low-incidence settings. J. Clin. Microbiol., 2023, vol. 61, no. 6, pp. e0029523. https://doi.org/10.1128/jcm.0029523

18. Chang A., Wu C.Z., Lin J.D., Lee C.N., Tsai K.Y., Wu P.H., Hsieh A.T. Prevalence and risk factors for latent tuberculosis among diabetes patients in Taiwan: a cross-sectional study. J. Infect. Dev. Ctries., 2022, vol. 16, no. 4, pp. 644-649. https://doi.org/10.3855/jidc.15839

19. Chin K.L., Anibarro L., Sarmiento M.E., Acosta A. Challenges and the way forward in diagnosis and treatment of tuberculosis infection. Trop. Med. Infect. Dis., 2023, vol. 8, no. 2, pp. 89. https://doi.org/10.3390/tropicalmed8020089

20. Cohen A., Mathiasen V.D., Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur. Respir. J., 2019, vol. 54, no. 3, pp. 1900655. https://doi.org/10.1183/13993003.00655-2019

21. Colangeli R., Gupta A., Vinhas S.A., Chippada Venkata U.D., Kim S., Grady C., Jones-López E.C., Soteropoulos P., Palaci M., Marques-Rodrigues P., Salgame P., Ellner J.J., Dietze R., Alland D. Mycobacterium tuberculosis progresses through two phases of latent infection in humans. Nat. Commun., 2020, vol. 11, no. 1, pp. 4870. https://doi.org/10.1038/s41467-020-18699-9

22. Erbağc E., Koç Yıldırım S., Hapa F.A. Evaluation of serial QuantiFERON-TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti-IL-17 treatment (secukinumab and ixekizumab): real-world data from a tuberculosis-endemic country. Australas J. Dermatol., 2024, vol. 65, no. 7, pp. 567-575. https://doi.org/10.1111/ajd.14340

23. Faujdar J., Gupta P., Natrajan M., Das R., Chauhan D.S., Katoch V.M., Gupta U.D. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Indian J. Med. Res., 2011, vol. 134, no. 5, pp. 696-703. https://doi.org/10.4103/0971-5916.90999

24. Flynn J.L., Chan J. Immune cell interactions in tuberculosis. Cell, 2022, vol. 185, no. 25, pp. 4682-4702. https://doi.org/10.1016/j.cell.2022.10.025

25. Garlant H.N., Ellappan K., Hewitt M., Perumal P., Pekeleke S., Wand N., Southern J., Kumar S.V., Belgode H., Abubakar I., Sinha S., Vasan S., Joseph N.M., Kempsell K.E. Evaluation of host protein biomarkers by ELISA from whole lysed peripheral blood for development of diagnostic tests for active tuberculosis. Front Immunol., 2022, no. 13, pp. 854327. https://doi.org/10.3389/fimmu.2022.854327

26. Ghanaie R.M., Karimi A., Azimi L., James S., Nasehi M., Mishkar A.P., Sheikhi M., Fallah F., Tabatabaei S.R., Hoseini-Alfatemi S.M. Diagnosis of latent tuberculosis infection among pediatric household contacts of Iranian tuberculosis cases using tuberculin skin test, IFN- γ release assay and IFN-γ-induced protein-10. BMC Pediatr., 2021, vol. 21, no. 1, pp. 76. https://doi.org/10.1186/s12887-021-02524-3

27. Gharamaleki O.G., Colijn C., Sekirov I., Johnston J.C., Sobkowiak B. Early prediction of Mycobacterium tuberculosis transmission clusters using supervised learning models. Sci. Rep., 2024, vol. 14, no. 1, pp. 27652. https://doi.org/10.1038/s41598-024-78247-z

28. Global tuberculosis report, 2022. Geneva, World Health organization, 2022. Licence: cc bY-Nc-sa 3.0 iGo.

29. Global tuberculosis report, 2024. Geneva, World Health Organization, 2024. Licence: CC BY-NC-SA 3.0 IGO.

30. Godoy P. Guidelines on controlling latent tuberculosis infection to support tuberculosis elimination. Rev. Esp. Sanid. Penit., 2021, vol. 23, no. 1, pp. 28-36. https://doi.org/10.18176/resp.00028

31. Godoy S., Alsedà M., Parrón I., Millet J.P., Caylà J.A., Follia N., Carol M., Orcau A., Toledo D., Ferrús G., Plans P., Barrabeig I., Clotet L., Domínguez A., March-Llanes J., Godoy P., On behalf of the transmission of tuberculosis in Catalonia Spain Working Group. Exposure time to a tuberculosis index case as a marker of infection in immigrant populations. Pathogens, 2025, vol. 14, no. 2, pp. 175. https://doi.org/10.3390/pathogens14020175

32. Gong W., Wu X. Differential diagnosis of latent tuberculosis infection and active tuberculosis: a key to a successful tuberculosis control strategy. Front Microbiol., 2021, no. 12, pp. 745592. https://doi.org/10.3389/fmicb.2021.745592

33. Gupta R.K., Calderwood C.J., Yavlinsky A., Krutikov M., Quartagno M., Aichelburg M.C., Altet N., Diel R., Dobler C.C., Dominguez J., Doyle J.S., Erkens C., Geis S., Haldar P, Hauri A.M., Hermansen T., Johnston J.C., Lange C., Lange B., van Leth F., Muñoz L., Roder C., Romanowski K., Roth D., Sester M., Sloot R., Sotgiu G., Woltmann G., Yoshiyama T., Zellweger J.P., Zenner D., Aldridge R.W., Copas A., Rangaka M.X., Lipman M., Noursadeghi M., Abubakar I. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med., 2020, vol. 26, no. 12, pp. 1941-1949. https://doi.org/10.1038/s41591-020-1076-0

34. Houben R.M., Dodd P.J. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLos Med., 2016, vol. 13, no. 10, pp. e1002152. https://doi.org/10.1371/journal.pmed.1002152

35. Hu K., Liu Y., Sha Y., Zhang M., Jian L., Duan Y., Lv. C., Kuang Y. Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China. Clin. Exp. Dermatol., 2025, vol. 50, no. 6, pp. 1107-1115. https://doi.org/10.1093/ced/llae549

36. Knight G.M., McQuaid C.F., Dodd P.J., Houben R.M.G.J. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis., 2019, vol. 19, no. 8, pp. 903-912. https://doi.org/10.1016/S1473-3099(19)30307-X

37. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, World Health Organization, 2018. PMID: 30277688.

38. Li L.S., Yang L., Zhuang L., Ye Z.Y., Zhao W.G., Gong W.P. From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning. Mil. Med. Res., 2023, vol. 10, no. 1, pp. 58. https://doi.org/10.1186/s40779-023-00490-8

39. Lin W.C., Lin H.H., Lee S.S., Sy C.L., Wu K.S., Chen J.K., Tsai H.C., Chen Y.S. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country. J. Microbiol. Immunol. Infect., 2016, vol. 49, no. 5, pp. 729-736. https://doi.org/10.1016/j.jmii.2014.08.010

40. Luo Y., Xue Y., Liu W., Song H., Huang Y., Tang G., Wang F., Wang Q., Cai Y., Sun Z. Development of diagnostic algorithm using machine learning for distinguishing between active tuberculosis and latent tuberculosis infection. BMC Infect. Dis., 2022, vol. 22, no. 1, pp. 965. https://doi.org/10.1186/s12879-022-07954-7

41. Luo Y., Xue Y., Song H., Tang G., Liu W., Bai H., Yuan X., Tong S., Wang F., Cai Y., Sun Z. Machine learning based on routine laboratory indicators promoting the discrimination between active tuberculosis and latent tuberculosis infection. J. Infect., 2022, vol. 84, no. 5, pp. 648-657. https://doi.org/10.1016/j.jinf.2021.12.046

42. Malinová J., Hájková M., Hatalová A., Šteňová E. Risk of latent tuberculosis in the cohort of patients with rheumatoid arthritis in Slovakia. Epidemiol. Mikrobiol. Imunol., 2021, vol. 70, no. 2, pp. 83-90.

43. Migliori G.B., Thong P.M., Akkerman O., Alffenaar J.W., Álvarez-Navascués F., Assao-Neino M.M., Bernard P.V. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January-April 2020. Emerg. Infect. Dis., 2020, vol. 26, no. 11, pp. 2709-2712. https://doi.org/10.3201/eid2611.203163

44. Mohammadnabi N., Shamseddin J., Emadi M., Bodaghi A.B., Varseh M., Shariati A., Rezaei M., Dastranj M., Farahani A. Mycobacterium tuberculosis: the mechanism of pathogenicity, immune responses, and diagnostic challenges. J. Clin. Lab. Anal., 2024, vol. 38, no. 23, pp. e25122. https://doi.org/10.1002/jcla.25122

45. Mubeen S.A., Vats D., Yadav K., Sharma A., Singh A. CD14++CD16- classical monocyte subset secreting IL-1ß and IL-10 is associated with 'Tuberculosis Resisters' phenotype. Hum. Immunol., 2025, vol. 86, no. 2, pp. 111240. https://doi.org/10.1016/j.humimm.2025.111240

46. Ndzi E.N., Nkenfou C.N., Pefura E.W.Y., Mekue L.C.M., Guiedem E., Nguefeu C.N., Ngoufack M.N., Elong E., Yatchou L.G., Ndjolo A., Kuiate J.R. Tuberculosis diagnosis: algorithm that may discriminate latent from active tuberculosis. Heliyon, 2019, vol. 5, no. 10, pp. e02559. https://doi.org/10.1016/j.heliyon.2019.e02559

47. Ogawa Y., Harada M., Hashimoto K., Kamijo Y. Prevalence of latent tuberculosis infection and its risk factors in Japanese hemodialysis patients. Clin. Exp. Nephrol., 2021, vol. 25, no. 11, pp. 1255-1265. https://doi.org/10.1007/s10157-021-02093-w

48. Pagnoncelli M., Arosio M., Genovesi A., Napolitano G., Farina C. Performance of the T-SPOT.TB test in patients with indeterminate QuantiFERON-TB Gold Plus results: proposal for an algorithm for the diagnosis of latent tuberculosis infection. Infez. Med., 2024, vol. 32, no. 4, pp. 525-531. https://doi.org/ 10.53854/liim-3204-11

49. Peng L., Ma W., Zhong L., Yang J., Wu H., Zhu L., Huang X., Yang R., Li B., Ma W., Wu X., Song J., Luo S., Bao F., Liu A. Diagnostic accuracy of Mycobacterium tuberculosis antigen-based skin tests (TBSTs) for tuberculosis infection compared with TST and IGRA: a network meta-analysis. Pathogens, 2024, vol. 13, no. 12, pp. 1050. https://doi.org/10.3390/pathogens13121050

50. Petruccioli E., Chiacchio T., Navarra A., Vanini V., Cuzzi G., Cimaglia C., Codecasa L.R., Pinnetti C., Riccardi N., Palmieri F., Antinori A., Goletti D. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. J. Infect., 2020, vol. 80, no. 5, pp. 536-546. https://doi.org/10.1016/j.jinf.2020.02.009

51. Pipitò L., Ricci E.D., Maggi P., De Socio G.V., Pellicano G.F., Trizzino M., Rubino R., Lanzi A., Crupi L., Capriglione I., Squillace N., Nunnari G., Di Biagio A., Bonfanti P., Cascio A; CISAI Study Group. Screening for latent tuberculosis infection in people living with HIV: TUBHIVIT Project, a multicenter Italian study. Viruses, 2024, vol. 16, no. 5, pp. 777. https://doi.org/10.3390/v16050777

52. Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection. Geneva, World Health Organization, 2022 (WHO/UCN/TB/2022.1). Licence: CC BY-NC-SA 3.0 IGO.

53. Reichler M.R., Hirsch C., Yuan Y., Khan A., Dorman S.E., Schluger N., Sterling T.R. Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. BMC Infect. Dis., 2020, vol. 20, no. 1, pp. 553. https://doi.org/10.1186/s12879-020-05185-2

54. Reichler M.R., Khan A., Yuan Y., Chen B., McAuley J., Mangura B., Sterling T.R; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Duration of exposure among close contacts of patients with infectious tuberculosis and risk of latent tuberculosis infection. Clin. Infect. Dis., 2020, vol. 71, no. 7, pp. 1627-1634. https://doi.org/10.1093/cid/ciz1044

55. Robison H.M., Chapman C.A., Zhou H., Erskine C.L., Theel E., Peikert T., Lindestam Arlehamn C.S., Sette A., Bushell C., Welge M., Zhu R., Bailey R.C., Escalante P. Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection. Sci. Rep., 2021, vol. 11, no. 1, pp. 20544. https://doi.org/10.1038/s41598-021-99754-3

56. Runels T., Ragan E.J., Ventura A.S., Winter M.R., White L.F., Horsburgh C.R., Samet J.H., Saitz R., Jacobson K.R. Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study. BMJ Open, 2022, vol. 12, no. 3, pp. e058751. https://doi.org/10.1136/bmjopen-2021-058751

57. Santos J.A., Duarte R., Nunes C. Host factors associated to false negative and indeterminate results in an interferon-γ release assay in patients with active tuberculosis. Pulmonology, 2020, vol. 26, no. 6, pp. 353-362. https://doi.org/10.1016/j.pulmoe.2019.11.001

58. Scriba T.J., Penn-Nicholson A., Shankar S., Hraha T., Thompson E.G., Sterling D., Nemes E., Darboe F., Suliman S., Amon L.M., Mahomed H., Erasmus M., Whatney W., Johnson J.L., Boom W.H., Hatherill M., Valvo J., De Groote M.A., Ochsner U.A., Aderem A., Hanekom W.A., Zak D.E. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathog., 2017, vol. 13, no. 11, pp. e1006687. https://doi.org/10.1371/journal.ppat.1006687

59. Starshinova A. Difficulties in diagnosing tuberculosis infection in childhood. The Lancet Infectious Diseases, 2025, vol.25, no. 2, pp. 140-141. https://doi.org/10.1016/S1473-3099(24)00569-3

60. Surve S., Bhor V., Gounder V., Munne K., Begum S., Naukariya K., Gomare M., Puri V., Tipre P., Sutar N., Dhawale A., Naik R., Jaiswal A., Bhonde G., Shikhare M., Kamble R., Dalvi R., Kamat S., Tryambake V., Chauhan S., Shah I. Management implications of latent TB among under-five children at risk: insights from a community study in Mumbai, India. Pediatr. Pulmonol., 2025, vol. 60, no. 6, pp. e27336. https://doi.org/10.1002/ppul.27336

61. Uplekar M., Weil D., Lonnroth K., Jaramillo E., Lienhardt C., Dias H.M., Falzon D., Floyd K., Gargioni G., Getahun H., Gilpin C., Glaziou P., Grzemska M., Mirzayev F., Nakatani H., Raviglione M., for WHO's Global TB Programme. WHO's new end TB strategy. Lancet, 2015, vol. 385, no. 9979, pp. 1799-1801. https://doi.org/10.1016/S0140-6736(15)60570-0

62. Vasiliu A., Martinez L., Gupta R.K., Hamada Y., Ness T., Kay A., Bonnet M., Sester M., Kaufmann S.H.E., Lange C., Mandalakas A.M. Tuberculosis prevention: current strategies and future directions. Clin. Microbiol. Infect., 2024, vol. 30, no. 9, pp. 1123-1130. https://doi.org/10.1016/j.cmi.2023.10.023

63. White H.A., Baggaley R.F., Okhai H., Patel H., Stephenson I., Bodimeade C., Wiselka M.J., Pareek M. The impact, effectiveness and outcomes of targeted screening thresholds for programmatic latent tuberculosis infection testing in HIV. AIDS, 2022, vol. 36, no. 14, pp. 2035-2044. https://doi.org/10.1097/QAD.0000000000003364

64. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva, World Health Organization, 2022.

65. Wu J., Bai J., Wang W., Xi L., Zhang P., Lan J., Zhang L., Li S. ATB discrimination: an in silico tool for identification of active tuberculosis disease based on routine blood test and T-SPOT.TB detection results. J. Chem. Inf. Model., 2019, vol. 59, no. 11, pp. 4561-4568. https://doi.org/10.1021/acs. jcim.9b00678

66. Xie L., Zhu G., Long S., Wang M., Cheng X., Dong Y., Wang C., Wang G. Identification of MORN3 and LLGL2 as novel diagnostic biomarkers for latent tuberculosis infection using machine learning strategies and experimental verification. Ann. Med., 2024, vol. 56, no. 1, pp. 2380797. https://doi.org/10.1080/07853890.2024.2380797

67. Yoon S.J., Kwon W.K., Jeong M.J., Lee J., Oh H.Y., Huh W., Jang H.R., Joh J.W., Kim J.M., Choi G.S., Kim S.J., Park J.B., Lee K.W., Sinn D.H., Choi J.O., Kang E.S. Comparative evaluation of QuantiFERON-TB Gold Plus for diagnosis of latent tuberculosis infection during solid organ transplantation. Korean J. Transplant., vol. 34, no. 1, pp. 8-14. https://doi.org/10.4285/kjt.2020.34.1.8

68. Zellweger J.P., Sotgiu G., Corradi M., Durando P. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). Med. Lav., 2020, vol. 111, no. 3, pp. 170-183. https://doi.org/10.23749/mdl.v111i3.9983

69. Zeng J., Zhu D., Zhang H., Lin T., Song T. IGRA-based INH regimen for prevention of active tuberculosis after kidney transplantation: a single-centre retrospective study. Int. J. Antimicrob. Agents, 2024, vol. 63, no. 3, pp. 107093. https://doi.org/10.1016/j.ijantimicag.2024.107093

70. Zhong J., Li Y., Chen Y., Shi X., Zhou B., Ruan G., Zhang L., Liu X; ETHERTB study team. Systemic vasculitis with latent tuberculosis infection and associated factors: a cross-sectional multicenter study. Clin. Rheumatol., 2025, vol. 44, no. 3, pp. 1269-1277. https://doi.org/10.1007/s10067-024-07279-7

71. Zhou G., Guo X., Cai S., Zhang Y., Zhou Y., Long R., Zhou Y., Li H., Chen N., Song C. Diabetes mellitus and latent tuberculosis infection: an updated meta-analysis and systematic review. BMC Infect. Dis., 2023, vol. 23, no. 1, pp. 770. https://doi.org/10.1186/s12879-023-087